These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27941111)

  • 1. Combining an antiviral with rituximab in EBV-related haemophagocytic lymphohistiocytosis led to rapid viral clearance; and a comprehensive review.
    Stefanou C; Tzortzi C; Georgiou F; Timiliotou C
    BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 27941111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
    Chellapandian D; Das R; Zelley K; Wiener SJ; Zhao H; Teachey DT; Nichols KE;
    Br J Haematol; 2013 Aug; 162(3):376-82. PubMed ID: 23692048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab.
    Thompson G; Pepperell D; Lawrence I; McGettigan BD
    BMJ Case Rep; 2017 Feb; 2017():. PubMed ID: 28228435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of rituximab in SARS-CoV-2-positive renal transplant recipient with EBV reactivation and probable haemophagocytic lymphohistiocytosis.
    Chan D; Karimi S; Follows G; Torpey N; Suchanek O
    CEN Case Rep; 2023 Feb; 12(1):27-31. PubMed ID: 35729310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
    Balamuth NJ; Nichols KE; Paessler M; Teachey DT
    J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
    Meng GQ; Wang JS; Wang YN; Wei N; Wang Z
    Int Immunopharmacol; 2021 Jul; 96():107606. PubMed ID: 33826999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis.
    Bosman G; Langemeijer SM; Hebeda KM; Raemaekers JM; Pickkers P; van der Velden WJ
    Neth J Med; 2009 Sep; 67(8):364-5. PubMed ID: 19767670
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn's disease patient on azathioprine, successfully treated with rituximab.
    Fitzgerald MP; Armstrong L; Hague R; Russell RK
    J Crohns Colitis; 2013 May; 7(4):314-7. PubMed ID: 22640698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis subsequent to rabbit antithymocyte globulin administration and successfully treated with rituximab in a patient with aplastic anemia].
    Nagata H; Fujino T; Muramatsu A; Kawaji Y; Kuriyama K; Oshiro M; Hirakawa Y; Iwai T; Uchiyama H
    Rinsho Ketsueki; 2018; 59(4):407-413. PubMed ID: 29743400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbiological findings and treatment of EBV-associated hemophagocytic lymphohistiocytosis: a case report.
    Przybylski M; Dzieciatkowski T; Zduńczyk D; Jedrzejczak WW; Luczak M
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):247-52. PubMed ID: 20383798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report.
    Zhu M; Zhang J; Shi Q; Sun X; Wang H; Sun M; Liu Y
    Iran J Immunol; 2023 Dec; 20(4):466-472. PubMed ID: 37873944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and outcome analysis of 83 childhood Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with HLH-2004 protocol].
    Xiao L; Xian Y; Dai BT; Su YC; Xiao JW; Zheng QC; Zhao XD; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):668-72. PubMed ID: 22339824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
    Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
    Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    El-Mallawany NK; Curry CV; Allen CE
    Br J Haematol; 2022 Jan; 196(1):31-44. PubMed ID: 34169507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis presenting with acute sensorineural hearing loss: a case report and review of the literature.
    Arslan F; Karagöz E; Beköz HS; Ceylan B; Mert A
    Infez Med; 2017 Sep; 25(3):277-280. PubMed ID: 28956548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis and follow-up study of Epstein-Barr virus associated-hemophagocytic lymphohistiocytosis in childhood].
    Lu G; Xie ZD; Shen KL; Wu RH; Jin YK; Yang S; Liu CY
    Zhonghua Er Ke Za Zhi; 2010 Feb; 48(2):121-6. PubMed ID: 20426937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein barr virus hemophagocytic lymphohistiocytosis related to rituximab use and immunopathogenetic insights.
    Papageorgiou SG; Tsiodras S; Siakallis G; Bazani E; Spathis A; Poulakou G; Korkolopoulou P; Panayiotides I; Pappa V
    Pathol Res Pract; 2016 Dec; 212(12):1194-1198. PubMed ID: 28340951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with severe cardiac complications.
    Kawamura Y; Miura H; Matsumoto Y; Uchida H; Kudo K; Hata T; Ito Y; Kimura H; Yoshikawa T
    BMC Pediatr; 2016 Oct; 16(1):172. PubMed ID: 27793118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy.
    Tejedor I; Tedbirt B; Carvalho P; Duval-Modeste AB; Joly P; Hébert V
    Melanoma Res; 2022 Dec; 32(6):485-487. PubMed ID: 36125885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emapalumab as a therapeutic intervention for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A case series.
    Wang W; Yuan X; Yu L; Pei F
    Medicine (Baltimore); 2024 Sep; 103(39):e39880. PubMed ID: 39331881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.